Are drug-eluting stents the future of SFA treatment?
J Cardiovasc Surg (Torino)
; 51(1): 115-9, 2010 Feb.
Article
en En
| MEDLINE
| ID: mdl-20081767
ABSTRACT
Drug-eluting stent (DES) technology was developed to prevent early thrombosis and late luminal loss to potentially improve long-term patency rates. Although favorable DES results have recently become available with the Zilver PTX and STRIDES studies, the high price of DES is a major drawback for this technology to become the golden standard for peripheral endovascular therapy in de novo femoro-popliteal (FP) lesions. Nevertheless, DES has the potential to make the difference and to establish itself as an important treatment option in patients presenting with TASC C&D FP lesions who are at high-risk for surgery and for the treatment of in-stent restenosis, where until now, no valuable treatment option has proven to be beneficial.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Arteria Poplítea
/
Arteriopatías Oclusivas
/
Angioplastia
/
Stents Liberadores de Fármacos
/
Arteria Femoral
Límite:
Humans
Idioma:
En
Revista:
J Cardiovasc Surg (Torino)
Año:
2010
Tipo del documento:
Article
País de afiliación:
Bélgica